Collagen itself does not contain hormones and is unlikely to cause hormonal breakouts
Its peptides are sold research use only, and in 2023 BPC-157 was formally placed by the FDA into an interim category of bulk substances flagged for significant safety risks, citing immunogenicity, impurities, and a lack of human safety data
IRE1, Inositol-Requiring Enzyme 1
sermorelin may increase IGF-1), compounded GI side effects (nausea, vomiting, constipation), potential fluid retention or joint symptoms from elevated growth hormone, and unknown long-term metabolic effects
Compounding advocates say that, although the drugs are not FDA-approved, they are still subject to rigorous quality control, in part due to post-2012 rule changes
Email support takes 2472 hours